{"id":"NCT02832063","sponsor":"AOBiome LLC","briefTitle":"Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris","officialTitle":"A Randomized, Double Blinded, Phase IIb/III, Decentralized Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Participants With Mild to Moderate Acne Vulgaris","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2016-08","primaryCompletion":"2017-07-19","completion":"2017-07-19","firstPosted":"2016-07-13","resultsPosted":"2022-09-16","lastUpdate":"2022-09-16"},"enrollment":372,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"BIOLOGICAL","name":"B244","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"B244 arm","type":"ACTIVE_COMPARATOR"},{"label":"Placebo arm","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to demonstrate the safety, tolerability and efficacy of B244 administered over 12 weeks to participants with mild to moderate acne vulgaris relative to placebo.","primaryOutcome":{"measure":"Number of Participants With Treatment RelatedAdverse Events","timeFrame":"16 weeks","effectByArm":[{"arm":"B244 Arm","deltaMin":10,"sd":null},{"arm":"Placebo Arm","deltaMin":9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":181},"commonTop":["Viral upper respiratory tract infection","Dry skin","Sinusitis","Upper respiratory tract infection","Hypertension"]}}